Skip to main content
Science / Explained
What We Don’t KnowArticle 1 of 5

Why does GLP-1 response vary so much between people?

Two patients on identical GLP-1 doses can lose dramatically different amounts of weight. One might shed 8 percent of their body weight while another loses 22 percent. The difference is not random, and it is not about willpower.

The answer appears to live in biology no one can test for yet.

Gut bacteria, genetics, and the way the body has managed weight over time all appear to shape how strongly someone responds. These factors seem to interact in ways that make one person's metabolism different from the next. But there is no predictive test. There is no way to know beforehand who will be a strong responder and who will be a modest one.

Doctors prescribe the same dose to everyone and then watch what happens. If the response is weak, they might increase it. If side effects are strong, they might lower it. But the early difference in outcome starts with biology that science has not yet mapped.

This individual variation is one of the most important unsolved questions in GLP-1 research. Understanding it could mean prescribing the right dose from the start instead of adjusting by trial and error. It could mean matching patients to the right compound for their unique metabolism.

Some of that variation may trace back to the microbiome, the trillions of bacteria that live in the gut and influence how the body processes food and signals. GLP-1 agonists appear to reshape these bacteria, and the bacteria appear to reshape how much GLP-1 the body makes naturally.

The loop runs in both directions, and we are just starting to map it.
One More Thing

The answer may live in the gut, not the genes.

Emerging research shows that gut bacteria composition influences how the body processes GLP-1 drugs. Different bacterial populations produce different levels of short-chain fatty acids. Those fatty acids affect how sensitive GLP-1 receptors are.

Two patients with identical genetics but different microbiomes may respond completely differently to the same dose. Precision medicine for metabolic drugs may not start with a blood test. It may start with a stool sample.

Next →
What happens to the brain after years on GLP-1?
References07 sources
  1. Wilding JPH, Batterham RL, Calanna S, et al. · 2021
    Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
    N Engl J Med 384(11):989-1002, waterfall plot demonstrates inter-patient response distribution
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. · 2022
    Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).
    N Engl J Med 387(3):205-216
  3. Klemets A, Reppo I, Krigul KL, Volke V, Aasmets O, Org E. · 2026
    Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake.
    Sci Rep 16(1):6126, first prospective study testing microbiome as predictor of semaglutide response (n=20, T2D)
  4. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. · 2016
    From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites.
    Cell 165(6):1332-1345
  5. Depommier C, Everard A, Druart C, et al. · 2019
    Supplementation with Akkermansia muciniphila in overweight and obese human volunteers.
    Nat Med 25(7):1096-1103
  6. Shang J, Liu F, Zhang B, Dong K, et al. · 2021
    Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus.
    PeerJ 9:e11128
  7. Smits MM, et al. · 2021
    Counter-evidence: Liraglutide did NOT alter microbial diversity in this RCT (n=51).
    Diabetes Metab 47(5):101223, null result included for honest framing
Why does GLP-1 response vary so much between people? · Catalyst / Science Explained · Catalyst